Lilly VP joins Reliant as chief operating officer
Lilly VP-Corporate Business Development Joseph Zakrzewski will begin serving as Reliant chief operating officer Feb. 1. The operations position is new at Reliant, which had FDA approvals for Omacor (omega-3 acid ethyl esters) and Antara (fenofibrate) in November 2004. Lilly has not yet named a successor for Zakrzewski. Reliant also named a new CFO; Robert Ferguson began at Reliant Jan. 17, succeeding Larry Gyenes...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.